Request for BD FACSAria Fusion Cell Sorter ShEEP Application

请求 BD FACSAria 融合细胞分选仪 SheEEP 申请

• 批准号: 9905139
• 负责人: Michal A Olszewski
• 金额: --
• 依托单位: VETERANS HEALTH ADMINISTRATION
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-09-01 至 2020-09-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9905139
• 关键词: Adoptive Cell Transfers; Adoptive Transfer; Affect; Animals; Antigens; Applications Grants; Award; Bacterial Pneumonia; Behavior; Biological Assay; Biological Markers; Biological Sciences; Biology; Biomedical Engineering; Biomedical Research; CD4 Positive T Lymphocytes; CD8-Positive T-Lymphocytes; Cancer Biology; Cell Separation; Cell Survival; Cell fusion; Cells; Central Nervous System Infections; Chronic Obstructive Airway Disease; Chronic lung disease; Clinical; Collaborations; Collection; Communicable Diseases; Complex; Complex Mixtures; Data; Data Analyses; Data Collection; Dendritic Cells; Development; Disease; Disease model; Drug Implants; Ensure; Equipment; Faculty; Faculty Recruitment; Flow Cytometry; Fluorescence; Funding; Future; Genes; Genetic Transcription; Genomics; Gold; Health; Health Care Research; Healthcare Systems; Immune; Immune System Diseases; Immune system; Immunology; Immunosuppression; Immunotherapeutic agent; In Vitro; Individual; Investigation; Laboratories; Learning; Lung diseases; Malignant - descriptor; Malignant Neoplasms; Methods; Microglia; Minor; Molecular; Natural Killer Cells; Neurodegenerative Disorders; Pathogenesis; Pathology; Patients; Pattern; Physiology; Population; Process; Proteomics; RNA; Research; Research Activity; Research Personnel; Sampling; Services; Sheep; Site; Solid; Sorting - Cell Movement; Specificity; Specimen; Stains; Sterility; Students; Subgroup; System; Techniques; Technology; Testing; Therapeutic Intervention; Time; Tissues; Traumatic CNS injury; Tumor Stem Cells; Veterans; Viral Pneumonia; base; cell type; cost; design; experimental study; high risk; implantable device; improved; instrument; leukemia; macrophage; neoantigens; neoplasm immunotherapy; neuropathology; neutrophil; new technology; new therapeutic target; novel; novel marker; novel strategies; oncology; population based; pre-clinical therapy; programs; response; single cell sequencing; single-cell RNA sequencing; therapeutic target; training opportunity; transcriptome; translational study; vector

This proposal is for a high capacity flow cytometry sorter BD FACSAria Fusion Cell Sorter to allow 6 Major Users (Merit Award funded PIs) and 7 Minor Users at the VA Ann Arbor Health Care System (VAAAHS) to conduct Multi-parameter flow cytometry cell sorting to isolate highly purified cell subsets for subsequent analysis, experimental manipulations, and studies. Our research focuses on cellular and molecular mechanisms of diseases that preferentially affect veterans: COPD, neurodegenerative disorders and CNS trauma, solid cancers and leukemias, the deployment-related lung disease and group of infectious complications for which veterans have higher risk. Involvement of specific and frequently rare cell subsets and their unique responses are increasingly found to influence these conditions and need to be studied. New experimental approaches, such as single-cell RNA sequencing, cellular vector deliveries for immunotherapeutic approaches, and adoptive transfers, all rely on high-purity cell sorting that must be performed rapidly, precisely, and aseptically to acquire specific cell populations with high viability. These needs are not being adequately met at the VAAAHS. Requested FACS sorter, presently unavailable at our VA station, will allow for collection of rare cell populations based on their expression of a unique set of multiple specific markers that would otherwise be impossible or very difficult to obtain. The high capacity sorter will allow for sorting in a timely fashion (to maintain cell viability, sterility and unaltered activation state) while working on multiple samples. Our diverse group of users will be able to 1) effectively collect quantitative data from small and precious samples; 2) use of highly specific subsets of cells in further assays like RNA transcriptome analysis, single-cell sequencing, proteomics, gene array analysis, etc; 3) generate cells for adoptive transfer experiments and preclinical therapy tests; 4) isolate and study purified cell subsets from clinical samples and implanted devices to discover new biomarkers, therapeutic targets, and to advance design of therapeutic implants. Introducing these new capabilities will enhance quality of current studies and increase efficiency and throughput. It will also enhance future grant applications of our faculty and create new learning opportunities for trainees at the VAAAHS site to ultimately benefit Veterans’ health.

本提案是一种高容量流式细胞仪bfacsaria融合细胞分选仪